The Roslin Institute in Edinburgh — where Dolly the sheep was cloned — has been working to create transgenic pigs as a source of organs for transplant to humans. But the future of such efforts appeared in doubt this week, following comments by researcher Ian Wilmut that Geron Bio-Med intended to cut back on the research.
Wilmut said that the California-based company — which was created by the purchase of the Roslin Institute's commercial arm Roslin Bio-Med by the US biotech company Geron (see Nature 399 , 92; 1999) — was concerned about the risks that xenotransplantation might create viral diseases in humans.
But Grahame Bulfield, director of the Roslin, told Nature on Monday that Wilmut was speaking in a personal capacity. In comments later confirmed by Geron Bio-Med he added that if the company were to abandon xenotransplantation work, it would be purely on the grounds of refocusing research priorities, and not viral risk.
Rights and permissions
About this article
Cite this article
Butler, D. Roslin backs off pig organ work. Nature 406, 663 (2000). https://doi.org/10.1038/35021260
Published:
Issue Date:
DOI: https://doi.org/10.1038/35021260